Posted by Michael Wonder on 17 Aug 2022
Samsung Bioepis and Organon announce FDA approval of citrate free high concentration Humira biosimilar Hadlima (adalimumab-bwwd)
17 August 2022 - Samsung Bioepis and Organon today announced the U.S. FDA has approved the citrate free, high concentration (100 mg/mL) formulation of Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab).
Hadlima will be available in pre-filled syringe and auto-injector options, and the auto-injector was specifically designed with the patient in mind.
